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Abstract: Background: Thrombocytopenia is common among head injury patients. However there is a paucity of 
literature on the effects of platelet transfusion and clinical outcome in this group. We conducted this study to compare the 
severity of injury, transfusion requirements, in hospital mortality in thrombocytopenic and non thrombocytopenic head 
injury patients, also to study the response to platelet transfusion. 
Materials & Methods: Retrospective cohort analysis of clinical, laboratory and blood bank parameters of head injury 
patients was performed over a six month period (Jan-June 2011). Thrombocytopenia was defined as platelet count < 
100109cells/L. Severity of head injury, hospital length of stay, transfusion requirements, presence of coagulopathy and 
hospital mortality were assessed. A 20% increase in platelet count from baseline, 24 hours post transfusion was 
considered appropriate response. H/o drug (cefaperazone and mannitol) intake, fever, symptomatic bleeding, and 
transfusion history (days of storage and blood group of transfused platelet, H/o other blood components transfused, and 
transfusion reaction) were compared. 
Results: A total of 139 thrombocytopenic patients and 87 non-thrombocytopenic patients were assessed. Severity of 
injury was significantly higher in  thrombocytopenic group (GCS 8.7±4.2; ISS 24.5 (0-75) as compared to the non 
thrombocytopenic group (GCS 12.3±4.1; ISS 6.7 (0-25); (p<0.001) 62.6% thrombocytopenic patients developed 
coagulopathy (p<0.04). Thrombocytopenia was a risk factor for mortality (p<0.001). Patients who received ABO matched 
platelets showed appropriate response. Coagulopathy, h/o of drugs, fever, and days of storage for platelet units had no 
correlation with transfusion response. 
Conclusion: Thrombocytopenic head injured patients have significantly higher severity of injury, increased ICU stay, 
incidence of coagulopathy and poorer prognosis. However a significant relation of clinical, patient and blood bank related 
factors with post transfusion platelet increment was not observed. Prospective studies are needed to determine 
predictors of ineffective platelet transfusion response in head injured patients. 
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INTRODUCTION 
Thrombocytopenia following traumatic injury plays a 
pivotal role in determining the prognosis of these 
patients and adjunct to coagulopathy can complicate 
their hospital course, especially for patients with 
traumatic brain injury (TBI), leading to secondary 
complications and worsen outcomes. The incidence of 
hemostatic abnormalities elevates with the increase in 
the severity of head injury
 
[1]. Carrick et al. studied 
moderate and severe TBI, reporting 46% thrombocyto- 
penia and 41% coagulopathy [2]. There are copious 
and varied etiologies for thrombocytopenia but mostly 
due to the exhaustion of the platelet pool via reduced 
production, increased consumption and destruction of 
platelets, along with abnormal sequestration, hemodilu- 
tion secondary to infusion of fluids [3]. 
Platelet transfusion therapy is a major component in 
the management of bleeding after trauma. Although 
rectification of thrombocytopenia and/or coagulopathy  
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with platelet transfusions has been associated with 
improved survival it’s not devoid of risk. Infectious and 
noninfectious complications with an increased risk of 
death [4], following platelet transfusion have time often 
been reported. 
Refractoriness or the failure to obtain satisfactory 
responses following platelet transfusion may result 
from immune or non-immune platelet destruction, due 
to the development of HLA or HPA antibodies in respo- 
nse to the donor platelet antigens. Patients clinical 
condition at the time of the transfusion i.e. bleeding 
complications, mucosal damage, fever, infections, used 
medication and characteristics of the transfused plate- 
lets i.e. days of storage of platelet bag and ABO 
compatibility, also influence post platelet transfusion 
response. However, an independent causal effect of 
platelet transfusions is unclear.  
This study was undertaken with the primary aim of 
determining the incidence of thrombocytopenia in TBI 
patients and to compare it with the severity of injury, 
development of coagulopathy, hospital length of stay 
and clinical outcome. Secondary objective was to 
evaluate platelet transfusion response in thrombocyto- 
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penic head injury patients, and assess causes for an 
inappropriate transfusion response. 
METHODS & METHODOLOGY 
Study Design 
Clinical, laboratory and blood bank records for all 
hospitalized head injury patients admitted from January 
through June 2011 were retrospectively assessed and 
evaluated. Patients with a history of platelet disorder, 
hematologic malignancy, chemotherapy, and splenec- 
tomy were excluded. The study group included head 
injury patients with a platelet count < 100  109 /L 
(thrombocytopenic), age and gender matched non-thro- 
mbocytopenic control group included head injury with 
platelet count of>100109cells/L. (study: control=3:2) 
Indications for Platelet Transfusions 
Platelet concentrates were transfused to thrombocy- 
topenic (platelet count < 1, 00,000/ c mm) head injury 
patients who required surgical cranial interventions 
according to standard protocol/ guidelines. The 
thrombocytopenic head injury patients who do not 
require surgical cranial interventions were kept under 
observation and platelets were transfused only if they 
had coagulopathy or develop bleeding complications.  
Ideally random donor platelets (RDP) (>5.51010 
platelets/unit) obtained from 450ml of blood, increases 
the recipient platelet count by 5000 to 10,000 / c mm. 
Thus post transfusion response was defined as an incr- 
ease of 20% in the 24 hours post transfusion platelet 
count from baseline (pre transfusion) [5]. Based on the 
above criteria the thrombocytopenic patient group was 
further grouped as responders and non-responders.  
STUDY VARIABLES 
Patient’s clinical and demographic data was extract- 
ed from the computerized patient record system 
maintained by the hospital and documented on a struc- 
tured proforma. Clinical, patient and blood bank parti- 
culars i.e. patient age, gender, diagnosis, blood group; 
on admission systolic blood pressure, respiratory rate, 
severity of injury [glassgow coma scale (GCS) & injury 
severity score (ISS)], duration of mechanical ventila- 
tion, ICU length of stay, hospital length of stay, and 
incidence of in hospital mortality were noted. Factors 
that could result in an inappropriate or reduced post 
transfusion platelet response i.e. fever, bleeding, sep- 
sis, coagulopathy, h/o cefaperazone, h/o heparin, h/o 
mannitol, h/o previous transfusions; days of storage of 
platelet bags, blood group and total number of platelet 
units transfused were documented. 
Laboratory investigation results i.e. complete 
blood counts and routine plasma based coagulation 
assays (PT, aPTT & INR) throughout hospital stay 
were extracted. Coagulopathy was defined as elevated 
international normalized ratio (INR > 1.6) and/or prothr- 
ombin time and/or activated partial thromboplastin time 
(PTT) greater than 1.5 times normal Sepsis was 
confirmed via blood culture positivity. 
STATISTICAL ANALYSIS 
Statistical analysis was performed for the compar- 
ison of parameters between the groups. STATA 11.0 
statistical software (STATA Corp, TX, USA) was used 
for analysis. Quantitative variables were assessed for 
approximate normal distribution. Continuous variables 
were converted to dichotomous variables (categorical) 
by using clinically important cutoff points for 
assessment. Quantitative variables that were normally 
distributed were summarized as mean ± S.D,and 
variables that were not normally distributed were 
summarized by median (range). Categorical data was 
expressed as frequency (percentage). Univariate 
analysis of the continuous variables between two 
groups was done using student’s t- test &Wilcoxons 
Rank Sum test and categorical data was analyzed 
using Pearson Chi Square test. Multivariate analysis of 
risk factors with step wise regression for significant 
parameters in both categories of patients was done 
and results expressed as odds ratio (OR) and 95 % 
confidence interval (95%CI) . A p value of 0.05 was 
considered to be statistically significant. 
RESULT 
Thrombocytopenia following Traumatic Brain Injury 
Records of 250 TBI patients were reviewed for the 
duration of the study, 27 patients were excluded due to 
incomplete records. 223 patients with complete records 
and compliance with the study inclusion criteria formed 
the study population.  
136 patients formed the thrombocytopenic group, 
76(55.8%) of them developed thrombocytopenia on 
admission, 24 (17.6%) patients on the second day, and 
36(26.6%) patients developed thrombocytopenia on the 
3
rd
 day or latter. 44 patients had >14 days of ICU stay. 
 Age, gender frequency, systolic blood pressure, 
and length of hospital stay had no significant 
association with thrombocytopenia. Table 1 
Thrombocytopenic patients had significantly lower 
GCS of 8.7±4.2 compared to 12.3±4.1 the non-
thrombocytopenic group (p<0.001). ISS score of 
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thrombocytopenic patients 24.5(0-75) was three 
times higher than the non-thrombocytopenic group 
(6.7(0-25)). 50.4% thrombocytopenic patients were 
critically injured (25 ISS) (p<0.001) Table 1. 
On admission levels of sodium (p=0.0003), 
potassium (p=0.03), creatinine (p=0.02), aspartate 
transaminase (p=0.001), alanine transaminase 
(p=0.007) and alkaline phosphates (p=0.01) statistically 
Table 1: Baseline Clinical and Demographic Data of Thrombocytopenic and Non Thrombocytopenic Head Injury Patients 
Variables Non Thrombocytopenic (n=87) Thrombocytopenic (n=136) P-Value 
Age (years) 33.2±17.2 36.2±17.0 0.19 
Male  72(83.7) 116(85.9) Gender 
Female  14(16.3) 19(14.0) 
0.65 
Glasgow Coma Score (GCS) 12.3±4.1 8.7±4.2 <0.001 
1-8 severe 17(21.8) 65(48.2) 
9-13 moderate 10(12.8) 38(28.2) 
Severity of head 
injury 
14-15 mild 51(65.4) 32(23.7) 
<0.001 
Injury severity score (ISS) # 6.7(0-25) 24.5(0-75) <0.001 
1-24  68(97.1) 67(49.6) Severity of injury* 
25&>25 critical 2(2.9) 68(50.4) 
<0.001 
Systolic BP (mm/Hg) 122.5±17.3 125.9±26.0 0.33 
90-130 normal 57(80.3) 90(66.2) Systolic BP 
(mm/Hg)* 
<90 &>130 abnormal 14(19.7) 46(33.8) 
0.03 
Total stay (days) # 22.5(0-127) 15.4(1-144) 0.24 
ICU stay (days) # 1.4±0.7 2.0±0.9 <0.0001 
Sodium (mg %) 136.1±6.7 139.6±7.1 0.0003 
Potassium (mg %) 3.8±0.7 3.6±0.7 0.03 
Urea# (mg %) 32.4(1.9-137) 37.6(9-205) 0.39 
Creatinine# (mg %) 0.7(0.2-6.3) 0.8(0.1-6.4) 0.02 
Bilirubin# (mg %) 0.9(0.3-2.7) 1.1(0.2-8.2) 0.50 
Aspartate transaminase # (U/L) 69.2(6.7-477) 135.8(8.3-1419) 0.001 
Alanine transaminase# (U/L) 53.3(0.7-329) 101.2(8-936) 0.007 
Alkaline phosphates# (U/L) 149.8(26-671) 96.5(0-320) 0.01 
Hemoglobin (g/dl) 11.4±2.8 10.3±2.4 0.001 
Hb> 9(g/dl) 69(79.3) 93(68.4) Anemia* 
Hb< 9(g/dl) 18(20.7) 43(31.6) 
0.07 
Hematocrit (g/dl) 35.1±8.6 31.1±8.6 0.009 
Total Leukocyte Count (/cumm) 11933.3±4382.2 10755.2±5027.3 0.07 
Platelet (lacs/cumm) 241.8±70.6 158.9±81.8 <0.0001 
Prothrombin time (sec) 13.7± 1.2 14.6±1.2 0.64 
Activated thromboplastin time (sec) 28.6±12.0 29.2±10.8 0.71 
International Normalization Ratio (INR) # 1.1(0.9-2.0) 2.0(0.9-1.9) <0.0001 
Yes  79(90.8) 132(97.1) Coagulopathy* 
No  8(9.2) 4(2.9) 
0.04 
Discharged 72(82.8) 64(47.1) Immediate 
Outcome* 
Dead 15(17.2) 72(52.8) 
<0.001 
Data Expressed as Mean±S.D, students t- test applied to compare between groups 
#Data Expressed as Median (IQR), Wilcoxons Rank sum test applied to compare between groups  
* Data Expressed as Frequency (percentage), Pearson’s Chi Square test applied to compare between groups 
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varied between the two groups Table 1. 
Forty three (31.6%) thrombocytopenic patients were 
anemic (Hb <9 mm/Hg) on admission compared to 18 
(20.7%) in the non-thrombocytopenic group. 132 
(97.1%) thrombocytopenic patients developed 
coagulopathy (p=0.04) Table 1. 
72(52.8%) of the thrombocytopenic patients died 
during the course of hospital stay, whereas only 
15(17.2%) died in the non-thrombocytopenic group 
(p<0.001) Table 1. 
On analysis of various factors associated with 
mortality in head injury patients, development of 
thrombocytopenia (Unadjusted Odds ratio 4.04; 95% CI 
2.2-7.2) was a significant risk factor and on multivariate 
logistic regression analysis revealed that thrombocyto- 
penic TBI patients have a 4.2 OR for in hospital 
mortality (95% CI 2.1-8.2) Table 2. 
Platelet Transfusion in Thrombocytopenic TBI Pati- 
ents 
Total of 1031 units of platelets were transfused to 
the thrombocytopenic patients, adverse effects were 
reported in 23. Only one patient got transfused with 
single donor platelet and rest were transfused with 
random donor platelets Table 3. 
Age, gender frequency, severity of injury and ICU 
length of stay were not found to be statistically signif- 
ycant. Ideally every unit of RDP obtained from 450ml of 
blood, increases the recipient platelet count by 5000 to 
10,000 / c mm. Increasing number of platelet transfus- 
ions is reported to significantly enhance the risk of refr- 
actoriness; oppositely we observed a statistically signi- 
ficant correlation between the number of A+ve platelet 
transfusion and appropriate response. Patients who 
received more A +ve platelet units 4(1-13) (median 
IQR) responded well compared to thrombocytopenic 
patients who received less 2(1-10) (p=0.05) Table 4. 
Fifty seven thrombocytopenic head injury patients 
received cefaperazone therapy and none received 
heparin, 48 received mannitol therapy; however history 
of drugs and anticoagulants were not observed to be 
statistically significant parameters of platelet 
transfusion response.  
H/O fever, bleeding, sepsis, coagulopathy and other 
risks associated with transfusion (transfusion reaction) 
were not found to be significantly associated with 
platelet transfusion response Table 4. 
Average days of storage for platelet units were 2.3 
days, which did not correlate with platelet transfusion 
response. 
Out of 136 thrombocytopenic patients receiving 
transfusion, for 73 (53.7%) the platelet count returned 
back to normal: 57 (out of 73) patients the platelet 
count returned back to normal within 24hrs post transf- 
usion (day1) and 16 (out of 73) platelet count returned 
back to normal after 24 hrs of transfusion. For 63 (46.3%) 
the platelet count did not return back to normal. 
Table 2: Multivariate Logistic Regression Analysis of Factors Associated with Mortality in Head Injury Patients 
Parameters Discharged 
(n=136) 
Dead 
(n=87) 
P Value Unadjusted Odds 
Ratio (95% CI) 
Adjusted Odds 
Ratio (95% CI) 
1-24 61(80.3) 74(57.4) 0.8(0.3-1.7) Injury severity 
score(ISS) 
25&>25 critical 15(19.7) 55(42.6) 
0.001 
0.8(0.6-0.4) 
- 
1-7 severe 53(40.5) 29(35.4) 0.1 
8-13  moderate 32(24.4) 16(19.5) 0.7(0.3-1.7) 
Glasgow coma 
score(GCS) 
14-15  mild 46(35.1) 37(45.1) 
0.33 
0.8(0.6-0.3) 
- 
>90-130 83(64.8) 64(81.0) Systolic blood 
pressure(mmHg) < 90 &> 130 45(35.2) 15(18.9) 
0.013 0.5(0.2-1.0) - 
Yes 129(94.9) 82(94.3) 
Coagulopathy 
No 7(5.1) 5(5.8) 
0.8 0.1 - 
Yes 28(21.1) 13(15.3) 
Sepsis 
No 150(78.9) 72(84.7) 
0.3 0.1 - 
Yes 97(74.1) 36(41.4) 4.04(2.2-7.2) 4.2(2.1-8.2) 
Thrombocytopenia 
No 34(25.9) 51(58.6) 
<0.001 
0.1 - 
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Table 3: Base Line Clinical Characteristics and 
Transfusion Data of Thrombocytopenic Trauma 
Patients 
Parameters Frequency (%) 
O+ve 31(22.7) 
A+ve 23 (17) 
B+ve 58 (42.1) 
AB+ve 14 (10.1) 
O-ve 4 (3) 
A-ve 3 (2.20) 
B-ve 3 (2.20) 
Patients blood group 
AB-ve 1 (0.7) 
Yes 23 (16.9) 
Transfusion reaction 
No 113 (83.08) 
Yes 96 (70.5) 
Mechanical ventilation 
No 40 (29.4) 
No 113 (83.08) Platelet transfused with 
same bd.gp 
(units) Yes 23 (16.9) 
Severe HI 71 (52.2) 
Moderate HI 22 (16.1) Clinical details 
Mild HI 43 (31.6) 
EDH 13 (9.5) 
SDH 57 (41.9) 
SAH 12 (8.8) 
ICH 1 (0.7) 
Contusion 52(38.2) 
CT findings 
Normal 2 (1.4) 
Yes 57 ( 41.9) History of Cefaperazone 
(gms) No 79 (58.08) 
Yes 57 (41.9) 
History of mannitol (ml) 
No 79 (57.8) 
Yes 9 (6.61) 
History of fever 
No 127 (93.34) 
Yes 64 (47.0) 
History of bleeding 
No 72 (53) 
Yes 63 (46.3) 
Circulatory failure 
No 73(53.7) 
Yes 37 (27.2) 
Sepsis 
No 99 (72.7) 
Yes 72 (52.9) 
Returned to normal 
No 64(47.3) 
Data Expressed as Frequency (percentage)  
HI: Head Injury; EDH: Epidural Haematoma; SDH: Subdural Haematoma;SAH: 
Subarachnoid Hemorrhage; ICH: Intracerebral Hemorrhage 
Multivariate logistic regression analysis revealed 
those thrombocytopenic head injury patients who 
transfused with platelet of same as well as different 
blood group are four times at risk for in hospital 
mortality (Adjusted Odds ratio 3.9; 95% CI 1.2-12.6) 
(p= 0.022) Table 5 
DISCUSSIONS 
Seventy-six head injury patients (56%) developed
thrombocytopenia on admission; direct correlation of 
thrombocytopenia with the severity of injury was seen 
in terms of a low GCS score and high ISS. 
Thrombocytopenia was also seen to be significantly 
associated with development of coagulopathy and 
worse outcome. Post transfusion platelet increment 
was not observed to be statistically associated with the 
presentation of fever, bleeding due to trauma, sepsis, 
and other transfusion associated risk. Thrombocyto- 
penic head injury patients who received both ABO 
compatible and incompatible platelets were three times 
at risk for poorer outcome. 
Similar to our study thrombocytopenia in trauma 
and surgical patients has been established as an 
independent marker for poor prognosis, increased 
bleeding, longer ICU stay and increased mortality. 
Sharma et al.
 
[6] reported an incidence of 
thrombocytopenia to be 55% in septic shock patients, 
with significant correlation to organ failure [SOFA score 
(P = 0.008)] and a 1.4 times risk of mortality and lower 
survival rate. 
Various studies have reported association with 
organ failure following thrombocytopenia in critically ill 
patients with high multiple organ dysfunction scores 
(MODS), simplified acute physiology scores (SAPS), 
and acute physiology and chronic health evaluation 
(APACHE) scores. [7-9], however organ failure was not 
assessed for the study patients. 
Hui et al. [4] conducted a systematic review of the 
prevalence, incidence, consequences and risk factors 
for thrombocytopenia in critically ill patients and 
reported that six studies have found thrombocytopenia 
to be an independent predictor of death. 
Moreau et al. [10] found that a 10% decline in 
platelet count on day 4 was associated with an 
increased mortality and Nijsten et al. [11] found that 
spontaneous platelet count recovery occurred fast in 
ICU survivors than in non survivors. 
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Similarly, Strauss et al. [8] found an association 
between a 30% decrease in platelet count during ICU 
stay and increased mortality, and Acka et al. [12] found 
that patients who had a poor post transfusion platelet 
count were more likely to have worsen outcomes. 
A gradual decrease in platelet counts over several 
days is indicative of worsening of the underlying 
disease and is often associated with multiorgan failure 
and consumptive coagulopathy due to bacterial or 
fungal infection [9]. we report a correlation between 
coagulopathy and thrombocytopenia, as platelets serve 
primary functions in maintenance of homeostasis. 
Consumption and subsequent exhaustion of platelets 
(from ongoing activation of coagulation) may induce 
severe bleeding, though micro clot formation
 
[13]. 
Table 4: Evaluation of transfusion associated risk factors and factors affecting platelet transfusion response in 
thrombocytopenic head injury patients 
Parameters Responders Non Responders P Value 
Age( in yrs) * 36.5±17.2 35.9±16.8 0.82 
Male 61(84.7) 55(87.3) 
Gender 
Female 11(15.3) 8(12.7) 
0.67 
A
+ve 
 Platelet (units) 4(1-13) 2(1-10) 0.05 
B
+ve
 Platelet  (units) 4(2-23) 4(1-34) 0.69 
AB
+ve
 Platelet (units) 2(1-11) 3.5(1-8) 0.19 
O
+ve
 Platelet (units) 4(1-15) 4(1-22) 0.19 
Total no. of platelet given (units) * 10.8±6.6 9.7±6.1 0.29 
Mean days of storage of platelet bag* 2.3±0.9 2.3±2.3 0.74 
Glasgow Coma Score 7(3-15) 8(3-15) 0.76 
Injury Severity Score* 24.1±9.6 25.3±11.4 0.50 
ICU stay*(days) 2(1-3) 2(1-3) 0.08 
Length of stay*(days) 13(1-144) 9(1-84) 0.26 
Red blood cells 2(1-9) 2(1-4) 0.95 
Platelet rich plasma (in units) * 3.7±1.9 3.9±1.23 0.68 
Fresh frozen plasma(in units) * 3.8±2.2 3.8±2.2 0.51 
No 41(56.2) 38(60.3) 
History of Cefaperazone(gms) 
Yes 32(43.8) 25(39.7) 
0.63 
No 39(54.2) 38(61.3) 
History of Mannitol (ml) 
Yes 24(38.7) 24(38.7) 
0.41 
No 60(82.2) 53(84.1) 
History of Transfusion reaction 
Yes 13(17.8) 10(15.9) 
0.76 
No 70(95.9) 57(90.5) 
History of Fever 
Yes 3(4.1) 6(9.5) 
0.30 
No 40(54.8) 32(50.8) 
History of Bleeding 
Yes 33(45.2) 31(49.2) 
0.64 
No 36(52.2) 33(52.3) 
Circulatory Failure 
Yes 33(47.8) 30(47.6) 
0.98 
No 49(71.0) 45(72.6) 
Sepsis 
Yes 20(28.9) 17(27.4) 
0.84 
Yes 71(97.3) 61(96.8) 
Coagulopathy 
No 2(2.7) 2(3.2) 
1.00 
Data Expressed as Median (IQR), Wilcoxons Rank sum test applied to compare between groups  
*Data Expressed as Mean±S.D, students t- test applied to compare between groups 
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Correction of thrombocytopenia with platelet 
transfusion has been associated with both improved 
and worsened survival; however an independent 
causal effect of platelet transfusions is unclear [14]. Out 
of 136 thrombocytopenic patients receiving transfusion 
in the present study, for 73(53.7%) thrombocytopenia 
was corrected as the post transfusion platelet count 
returned to normal and for 63 (46.3%) the platelet 
count did not return back to normal. 
Post transfusion platelet count is affected by the 
quality as well as the number of platelets transfused 
and also by the dilution of platelets in the patient’s 
blood volume. Slichter et al.
 
[15] reported a mean 
platelet increment of 12.0 (±15) x 10
9
 platelets/L, 24 
hours post transfusion, with a 27% of refractoriness. In 
our study inappropriate post transfusion platelet 
increment was seen in 46.3% patients, this response 
however was not found to correlate with any patient or 
product related factors. 
Literature suggests that the status of the spleen is 
the biggest factor affecting post transfusion platelet 
increments, [15] significant increases in post 
transfusion platelet increments were associated with 
prior splenectomy at both 1 and 18 to 24 hours after 
transfusion. Injury to the spleen with h/o of splenec- 
tomy were excluded in our study. Also older patient age 
has been shown to be associated with increased 
platelet increments but only at 1 hour after transfusion, 
in the present study no such association was observed 
which could be due to the fact that platelet increments 
were observed 24hrs post transfusion. Other factors 
reported to significantly enhance the risk of refractori- 
ness
 
[15, 16] are lymphocytotoxic antibody positivity, at 
least 2 pregnancies, male gender, heparin, fever, 
bleeding, increasing number of platelet transfusions 
and increasing weight. None of these were observed to 
significantly vary amongst responders and non respon- 
ders in the present study, although we did observe a 
statistically significant correlation between the number 
of A
+ve 
platelet transfusion and appropriate response. 
Heparin is the most commonly reported cause of 
drug-induced thrombocytopenia with a reported 
incidence between one and ten percent
 
[17]. Bleeding 
time is reported to be prolonged and this is dose 
dependent. Moxalactam (greater than 4 g per day for 
one week) consistently impairs platelet function and 
prolongs the bleeding time, whereas ceftriaxone and 
ceftizoxime (6 g per day) have no demonstrable effect 
on platelet function
 
[18]. Third generation cephalospo- 
rins other than moxalactam, such as cefotaxime, 
cefoperazone, ceftizoxime and ceftriaxone rarely impair 
platelet function [19]. Association of heparin was with 
significantly decreased 24 hours platelet increments 
after transfusion, was reported by Slichter et al. [15], 
this was not observed in our study, as none of the 
study group received heparin therapy. However in both 
Slichter et al. [15], and our study transfusion reaction, 
and sepsis were not associated with changes in post 
transfusion platelet increments. 32% patients had fever 
in their study, which was seen to be significantly 
associated with platelet increments; we did not observe 
significant associations, as only 6% of the thrombocy- 
topenic TBI patients developed fever. 
Immunological factors also contribute to platelet 
refractoriness, these contributions are relatively minor.
Transfusion of platelets of same blood group as the 
recipient was significantly associated with increment of 
post transfusion platelet count in our study. 
Similar to our study, Shastry et al. [20] also
 
reported 
that fever, bleeding, sepsis, disseminated intravascular 
coagulation and cyclosporine use, which are more 
common in the patients with refractoriness, were not 
observed to be statistically significant.  
Table 5: Statistical Evaluation of Factors Associated with Mortality in Thrombocytopenic Head Injury Patients 
Parameters Dead (n=72) Alive (n=64) P Value 
Unadjusted Odds Ratio 
(95%CI) 
Adjusted Odds Ratio 
(95%CI) 
Same 9(12.86) 13(20.63) 0.1 - 
Different 27(38.57) 34(53.97) 1.14(0.42-3.08) 1.420(0.48-4.15) 
Blood group of the 
platelet(units) 
Both 34(48.57) 16(25.40) 
0.02 
3.06(1.08-8.65) 3.93(1.22-12.64) 
No 48(66.67) 31(48.44) 0.1 - H/O Cefaperazone 
(gms) Yes 24(33.33) 33(51.56) 
0.03 
0.46(0.23-0.93) 0.28(0.12-0.64) 
Abnormal(<10&>50) 55(78.57) 59(93.65) 4.02(1.25-12.8) 4.63(1.19-17.91) 
Blood Urea (mg %) 
Normal(10-50) 15(21.43) 4(6.35) 
0.01 
0.1 - 
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LIMITATION 
Calculations such as the corrected count increment 
(CCI) and the percent platelet recovery (PPR), which 
take into account the number of platelets transfused 
and the patient’s blood volume have been suggested to 
give a more precise comparison of the post transfusion 
platelet responses were not calculated for the purpose 
of this study. 
CONCLUSION 
Thrombocytopenia following TBI is associated with 
worse outcomes, and platelet transfusion for the 
correction of thrombocytopenia and coagulopathy is a 
valuable management technique. However clinical, 
patient and blood bank related factors do play a vital 
role in the post transfusion platelet count increment.  
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